Skip to main content

Drug Interactions between mavorixafor and Sohonos

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

palovarotene mavorixafor

Applies to: Sohonos (palovarotene) and mavorixafor

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations and adverse effects of palovarotene, which is primarily metabolized by the isoenzyme. Pharmacokinetic modeling simulations suggest that coadministration of palovarotene with cimetidine, a weak CYP450 3A4 inhibitor, resulted in a slight increase in the Cmax and AUC of palovarotene of approximately 10%; however, the clinical significance is unknown. Increased concentrations of palovarotene may increase the risk of adverse effects such as dry skin, dry lips, alopecia, pruritus, erythema, paronychia, cellulitis, decubitus ulcer, xerophthalmia, night blindness, depression, mood alterations, and pseudotumour cerebri (benign intracranial hypertension).

MANAGEMENT: Caution and clinical monitoring are recommended if palovarotene is coadministered with weak CYP450 3A4 inhibitors. The benefits versus risks of coadministration should be assessed. Patients should be advised to notify their health care professional if they experience increased effects of palovarotene such as dry skin, dry lips, alopecia, pruritus, erythema, paronychia, cellulitis, decubitus ulcer, xerophthalmia, night blindness, depression, mood alterations, and pseudotumor cerebri.

Drug and food interactions

Major

palovarotene food

Applies to: Sohonos (palovarotene)

Grapefruit, pomelo, and juices or supplements containing these fruits may increase the blood levels of palovarotene, which may increase the risk and/or severity of side effects such as dry skin, dry lips, hair loss, skin rash, itching, skin and nail infection, dry eyes, night blindness, depression, and mood changes. It may also increase the risk of a rare, but potentially serious, condition called pseudotumor cerebri caused by increased pressure in the brain. Palovarotene should be taken with food at approximately the same time each day. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Major

mavorixafor food

Applies to: mavorixafor

Mavorixafor should be taken on an empty stomach after an overnight fast, 30 minutes before food. Do not consume grapefruit products during treatment with mavorixafor unless otherwise directed by your doctor. Grapefruit juice can increase the blood levels and adverse effects of mavorixafor, increasing the risk of experiencing a change in the electrical activity of your heart called QT prolongation, which can result in irregular heartbeats that can be life-threatening. You should seek immediate medical attention if you experience an irregular heartbeat or feel dizzy, lightheaded, or faint during treatment. Speak with your doctor or healthcare provider if you have any questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer